Loading clinical trials...
Loading clinical trials...
This phase Ib study includes two phases: dose escalation phase and safety expansion phase. During the dose escalation phase, successive cohorts of eligible patients (minimum 3 and maximum 6 evaluable...
Bring this clarity to your next appointment.
Keep all your medical notes and next steps in one place.
Lead Sponsor
Novartis Pharmaceuticals
NCT02600949 · Metastatic Colorectal Adenocarcinoma, Metastatic Pancreatic Ductal Adenocarcinoma, and more
NCT03050268 · Acute Leukemia, Adenomatous Polyposis, and more
NCT06423326 · Borderline Resectable Pancreatic Ductal Adenocarcinoma, Resectable Pancreatic Adenocarcinoma, and more
NCT07542041 · Pancreatic Cancer, Pancreatic Neoplasms, and more
NCT07283705 · Phase 2 Study, BMS-986504, and more
Massachusetts General Hospital Dept. of Mass General Hospital
Boston, Massachusetts
Memorial Sloan Kettering Cancer Center MSKCC - SC
New York, New York
University of Utah / Huntsman Cancer Institute Huntsman UT
Salt Lake City, Utah
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions